WEBVTT

1
00:00:00.810 --> 00:00:02.689 line:0%
Please see the end of the video for

2
00:00:02.690 --> 00:00:04.549 line:0%
important safety information,

3
00:00:04.550 --> 00:00:06.629 line:0%
including boxed warning, and visit

4
00:00:06.630 --> 00:00:08.229 line:0%
XEOMIN.com for full prescribing

5
00:00:08.230 --> 00:00:09.230 line:0%
information.

6
00:00:10.360 --> 00:00:12.079
Hello, my name's Warner Carr.

7
00:00:12.080 --> 00:00:14.039
I'm a allergist and clinical

8
00:00:14.040 --> 00:00:14.999
immunologist.

9
00:00:15.000 --> 00:00:16.759
It is my pleasure today to talk to

10
00:00:16.760 --> 00:00:18.839
you about immunogenicity associated

11
00:00:18.840 --> 00:00:20.859
with botulinum type

12
00:00:20.860 --> 00:00:22.779
A toxins for the treatment of

13
00:00:22.780 --> 00:00:24.279
movement disorders.

14
00:00:24.280 --> 00:00:25.979
Neutralizing antibodies are

15
00:00:25.980 --> 00:00:28.679
antibodies that your body makes and

16
00:00:28.680 --> 00:00:30.819
they're targeted against a pathogen

17
00:00:30.820 --> 00:00:32.739
or a toxin or something that

18
00:00:32.740 --> 00:00:35.159
your body sees as a foreign invader.

19
00:00:35.160 --> 00:00:36.899
And what they do is they neutralize

20
00:00:36.900 --> 00:00:38.519
the function of that foreign

21
00:00:38.520 --> 00:00:40.629
invader. Formation of

22
00:00:40.630 --> 00:00:42.569
neutralizing antibodies can

23
00:00:42.570 --> 00:00:44.469
lead to clinical resistance.

24
00:00:44.470 --> 00:00:46.149
If the patient is developing a

25
00:00:46.150 --> 00:00:48.349
neutralizing antibody against the

26
00:00:48.350 --> 00:00:50.509
therapy, you're going to see issues.

27
00:00:50.510 --> 00:00:52.629
You're going to see a decrease in

28
00:00:52.630 --> 00:00:53.929
effectiveness. You're going to see a

29
00:00:53.930 --> 00:00:55.149
dose creep.

30
00:00:55.150 --> 00:00:56.269
The patient's going to have to come

31
00:00:56.270 --> 00:00:58.229
back into the doctor's office more

32
00:00:58.230 --> 00:00:59.729
frequently.

33
00:00:59.730 --> 00:01:01.629
In patients that have these movement

34
00:01:01.630 --> 00:01:03.509
disorders, they're

35
00:01:03.510 --> 00:01:05.589 line:85%
going to be on these biological

36
00:01:05.590 --> 00:01:07.090 line:85%
therapies for the long term.

37
00:01:08.310 --> 00:01:10.589 line:85%
So it's very important, especially

38
00:01:10.590 --> 00:01:12.629 line:85%
in the young patient, the

39
00:01:12.630 --> 00:01:14.429 line:85%
teenagers and the adolescents, to

40
00:01:14.430 --> 00:01:16.689 line:85%
choose something that

41
00:01:16.690 --> 00:01:18.709 line:85%
has a very low potential for

42
00:01:18.710 --> 00:01:20.789 line:85%
the generation of a neutralizing

43
00:01:20.790 --> 00:01:22.769
antibody. A higher protein

44
00:01:22.770 --> 00:01:24.709 
load increases

45
00:01:24.710 --> 00:01:26.629 
your risk of developing

46
00:01:26.630 --> 00:01:27.630
an antibody,

47
00:01:28.790 --> 00:01:30.609
and developing in particular a

48
00:01:30.610 --> 00:01:32.609
neutralizing antibody.

49
00:01:32.610 --> 00:01:34.429
The immunogenicity

50
00:01:34.430 --> 00:01:36.189
of these biological products are

51
00:01:36.190 --> 00:01:38.229
very, very important.

52
00:01:38.230 --> 00:01:41.209
So much so that the FDA has

53
00:01:41.210 --> 00:01:43.349
a guidance document for

54
00:01:43.350 --> 00:01:46.499
any company that is developing

55
00:01:46.500 --> 00:01:48.529
these biological therapies.

56
00:01:48.530 --> 00:01:50.409 line:70%
When choosing a therapy,

57
00:01:50.410 --> 00:01:51.249 line:70%
especially when you're treating

58
00:01:51.250 --> 00:01:52.969 line:70%
patients with movement disorders,

59
00:01:52.970 --> 00:01:55.349 line:70%
it's very important to

60
00:01:55.350 --> 00:01:56.350 line:70%
think about immunogenicity.

61
00:01:57.110 --> 00:01:59.769
It's important to choose a

62
00:01:59.770 --> 00:02:01.189
product that has a very low protein

63
00:02:01.190 --> 00:02:02.049
load.

64
00:02:02.050 --> 00:02:04.529
Xeomin is just

65
00:02:04.530 --> 00:02:07.009
the biologically active 150

66
00:02:07.010 --> 00:02:08.579
Kilo-Dalton Toxin.

67
00:02:08.580 --> 00:02:10.119
And if you look at the clinical

68
00:02:10.120 --> 00:02:11.559
trials that were conducted to

69
00:02:11.560 --> 00:02:13.059 line:80%
support the approval of XEOMIN,

70
00:02:13.060 --> 00:02:15.339 line:80%
you'll see it's a very low incidence

71
00:02:15.340 --> 00:02:17.379 line:80%
of production of neutralizing

72
00:02:17.380 --> 00:02:18.380 line:80%
antibodies.

73
00:02:19.220 --> 00:02:21.199 line:80%
And in addition to that, in

74
00:02:21.200 --> 00:02:22.759 line:80%
those patients, and in the adult

75
00:02:22.760 --> 00:02:23.979 line:80%
population, there was only 9.

76
00:02:25.560 --> 00:02:27.719 line:80%
And in the adolescent population,

77
00:02:27.720 --> 00:02:29.179 line:80%
there was only 4.

78
00:02:29.180 --> 00:02:30.999 line:80%
In those patients, there was no

79
00:02:31.000 --> 00:02:32.959 line:80%
signs of clinical resistance.

80
00:02:32.960 --> 00:02:35.019
It's really my pleasure today to

81
00:02:35.020 --> 00:02:36.219
talk to you guys about

82
00:02:36.220 --> 00:02:38.759
immunogenicity and the importance

83
00:02:38.760 --> 00:02:40.819
of immunogenicity in

84
00:02:40.820 --> 00:02:43.039
treating patients with botulinum

85
00:02:43.040 --> 00:02:44.479
type A toxin that have movement

86
00:02:44.480 --> 00:02:45.480
disorders.